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INTRODUCTION 
Obstructive sleep apnoea (OSA) is increasingly seen as 
a major health threat globally. Affecting approximately 
2% of women and 4% of men in Western population 
[6], it is considered a frequent medical condition. 
 Recurring complete and/or partial collapses 
(apnoea and hypopnoea respectively) of the upper 
airways defined OSA. Based on the number of apnoeas 
and/or hypopnoeas per hour of sleep, known as the 
apnoea-hypopnoea index (AHI), OSA is categorized as 
mild, moderate and severe. Polysomnography (PSG) is 
the best tool to diagnose OSA [1]. Well known risk 
factors for OSA include obesity, aging, male sex, 
smoking and alcohol intake [2-5].  
 Excessive daytime sleepiness (EDS) or 
insomnia, nocturia and morning headaches, are 
common complaints of OSA patients, but some 
patients may be asymptomatic. Berlin Questionnaire 
[2] and Epworth Sleepiness Scale (ESS) [3], are 
examples of clinically helpful questionnaires available 
to detect high risk OSA patients.   
 OSA is still underdiagnosed mainly among 
Asian population partly due to lack of understanding 
on the pathophysiology, and limited access to the 
diagnostic and management facility [6]. The aim of 
this article is to focus on the current state-of-the-art in 
epidemiology, pathophysiology, diagnostic procedures 
and treatment selections for proper management of 
OSA, while considering specific patient populations, 
such as hypertensive, diabetic, obese and Asian 
patients. 
OSA diagnosis 
The diagnosis of OSA is often missed due to its 
complexity and unavailability of diagnostic modalities 
in certain centres. In order to standardize the 
diagnostic criteria for OSA, The American Association 
of Sleep Medicine (AASM) has come up with a 
guideline on how to diagnose obstructive sleep apnoea 
[24]. 
 The document was developed by the AASM 
committees which consist of renowned authorities in 
sleep medicine field.  The guidelines have outlined six 
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recommendations, in which four of them were strong 
recommendations.   
First recommendation: clinical tools, questionnaires 
and prediction algorithms cannot be used to diagnose 
OSA, even in the absence of PSG.  The grading for 
this recommendation is stated as strong 
recommendation. 
Second recommendation: PSG can be used to 
diagnose OSA in straightforward cases with signs and 
symptoms of moderate to severe OSA. The grading for 
this recommendation is also stated as strong 
recommendation. 
Third recommendation: if a single home sleep 
apnoea test is negative, inconclusive, or technically 
inadequate, polysomnography can be performed for 
the diagnosis of OSA. The grading for this 
recommendation is stated as strong recommendation. 
Fourth recommendation: in patients with significant 
cardiorespiratory disease, awake hypoventilation or 
suspicion of sleep related hypoventilation, chronic 
opioid medication use, history of stroke or severe 
insomnia and potential respiratory muscle weakness 
due to neuromuscular condition, PSG is the standard 
tool to diagnose OSA. The grading for this 
recommendation is stated as strong recommendation. 
Fifth recommendation: for OSA diagnosis, a split-
night diagnostic protocol PSG, is preferable compared 
to a full-night diagnostic protocol if clinically 
acceptable. 
Sixth recommendation: if the first PSG result is 
negative or inconclusive, a repeat PSG is needed.   
 Individuals with unexplained daytime 
sleepiness should be the target for OSA assessment. 
Appraisal of the common symptoms and risk factors 
for OSA should be included in the assessment [7-10]. 
Obesity is the best-documented risk factor for OSA. 
Accidental sleep episodes during wakefulness, daytime 
drowsiness, unrefreshing sleep, lethargy, insomnia, 
and snoring are amongst clinical symptoms for OSA 
[11-16]. In patients presenting with daytime 
drowsiness, which is a well-known OSA symptom 
most responsive to treatment, further evaluation for 
OSA may be warranted if other causes such as thyroid 
disease, gastro-oesophageal reflux disease, or other 
respiratory diseases have been ruled out. In assessing 
the symptom severity of OSA, sleepiness 
questionnaires, such as the ESS may assist, but it 
cannot assess the AHI due to its lack of sensitivity and 
specificity compared to PSG [22-29]. 
 AASM and the Center for Medicare & 
Medicaid Services have considered AHI score of at 
least 15 events per hour or at least 5 events per hour 
with symptoms (such as daytime somnolence and 
fatigue) as criteria for OSA diagnosis.  
 
Table 1 Four modes of sleep study available in the market: Type I, 
Type II, Type III and Type IV 
Mode  Definition 
Type I Type I is the standard recommended overnight PSG 
for OSA diagnosis, in which the test was done in a 
proper sleep lab, attended by sleep technician.  
Type II Type II is defined by a test whereby the full PSG with 
its monitoring devices can be done outside of the sleep 
laboratory, without the presence of sleep technician.  
Type III Type III device channels only measure four 
physiologic variables which include cardiac variable 
(eg, heart rate or an electrocardiogram), respiratory 
variables (eg, respiratory movement and airflow), and 
arterial oxygen saturation. Signals needed to determine 
sleep stages or sleep disruption were not recorded by 
the device. 
Type IV Type IV is also known as continuous single or dual 
bioparameter devices. This device can only record one 
or two variables and it can work without a technician. 
The channels usually measure arterial oxygen 
saturation and airflow. 
 
Type II, III, and IV monitors differ from PSG in terms 
of AHI estimation. For OSA prediction in various AHI 
cutoff levels, these monitors have a high positive 
likelihood ratio and low negative likelihood ratio. 
Performances are better in monitors with more 
channels compared to those with fewer channels. Type 
IV monitors are limited by their inability to distinguish 
obstructive from central sleep apnoea. Indirect data 
from studies comparing PSG monitors recommended 
that performances are better with type III monitors 
compared to type IV monitors in expecting AHI scores 
indicative of OSA. 3% to 20% data loss of has been 
observed for type III and IV monitors [22]. Inadequate 
clarification of results from the usage of type III 
monitors has been described in 13% to 20% of the 
evaluations, resulting from inadequate data [23]. There 
is no verified study on the usefulness of transportable 
monitors for complicated patients with serious 
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comorbid settings, such as chronic lung issues, 
cardiomyopathies, or brain disorders. Data is also 
lacking on head-to-head comparison on one monitor 
with the other [30].  
OSA treatment 
The guideline by the American College of Physicians 
(ACP) is intended to provide clinicians with evidence-
based recommendations that will have positive, long-
term effects on patients’ cardiovascular risk, as well 
overall health and quality of life [20]. Three 
recommendations have been suggested by the 
guidelines which can be used to tailor our OSA 
management.  
 First recommendation is to encourage weight 
loss in all overweight and obese patients diagnosed 
with OSA. There is strong evidence showing how 
weight loss interventions can reduce the 
apnoea/hypopnoea index (AHI) and improve 
symptoms. OSA severity can be categorized as mild, 
moderate and severe. In which, mild means having 5-
14 events per hr, moderate means 15-30 events per hr, 
and severe means having more than 30 events per hr. 
In patients with mild OSA, weight loss alone can be 
sufficient to normalize the apnoea/hypopnoea index, 
thereby reducing the need for continuous positive 
airway pressure (CPAP). In those with persistent OSA, 
weight loss may reduce the amount of positive airway 
pressure required, which can increase tolerance of and 
adherence to CPAP. However, weight loss alone may 
not be sufficient to reduce OSA in all patients. In 
obese patients, weight loss must be encouraged with 
another primary treatment. In a meta-analysis of 12 
published trials, weight loss produced substantial 
reductions in apnoea/hypopnoea index, however, 
almost all of the patients continued to have persistent 
OSA after significant weight reduction. So, while 
weight loss must always be urged in OSA patients, it 
should not be assumed that this intervention alone will 
be sufficient; patients need to be reassessed to 
determine whether OSA persists and if so, CPAP 
should be continued.  
 Second recommendation is to prescribe 
CPAP as the first-line treatment for OSA patients. 
CPAP is as critical as it is effective not only in 
reducing the AHI but also in improving sleep 
continuity and architecture and decreasing the sleep 
hypoxia that is associated with OSA. Because of the 
lack of adherence to CPAP, many new features have 
been added including heated humidification, broad 
pressure adjustments, and expiratory pressure relief. 
Again, it is critical that each patient’s needs be taken 
into consideration. Some patients, particularly those 
with mild forms of OSA, may not need CPAP and may 
benefit from positional therapy or weight loss. Other 
therapy such as surgery or mandibular advancement 
devices (MADs) may be better suited for some patients 
despite their lesser effectiveness when compared with 
CPAP [33].  
 Third recommendation suggests that for 
OSA patients who favour MAD or for those with side 
effects due to CPAP, MAD can be considered as an 
alternate therapy to CPAP. MADs can be considered 
for patients with moderate to severe OSA, those with 
apnoea/hypopnoea index values between 18-40 
events/hour, and for individuals who experienced 
adverse events on CPAP or who can’t tolerate using it. 
While CPAP is still considered to be primary therapy, 
for those who must use a mandibular advancement 
device, it can often be very effective. Patients may find 
it easier to be compliant with MAD than with CPAP. 
One group of researchers observed that MADs were 
able to provide appropriate decrease in obstructive 
events in 70% of patients with mild OSA, 48% of 
those with moderate OSA, and 42% of those with 
severe OSA [21]. The ACP concluded that, without 
sufficient evidence, it is unclear which patients will 
benefit from MADs. Data from several studies show 
that patients who are younger and thinner, with less 
severe OSA, may benefit more from the use of MADs. 
Although the ACP does not recommend surgery or 
pharmaceutical therapy for OSA, the ACP does 
acknowledge that it may work for certain patients. 
However, the documented efficacy rate ranges from 
20%-100%, thereby making it challenging to 
determine its true effect [29].  
OSA in hypertensive patients 
There is a rising trend in the incidence of OSA in 
patients with hypertension. 20%–40% of OSA patients 
have been detected amongst drug resistant 
hypertensives patients [25-28]. Since the earliest 
description of PSG, acute changes in cardiovascular 
parameters are known to accompany OSA events at 
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night. Wide fluctuations of blood pressure (BP) and 
heart rate, are well known acute effects which have 
been contributed by alternating obstructive apnoea and 
hyperventilation episodes during sleep [5]. 
 Few mechanisms have been associated with 
increased cardiovascular risk among OSA patients, 
which include autonomic alterations, reformed 
mechanics of ventilation leading to serious physiologic 
changes of negative intrathoracic pressure, alteration 
of renin–angiotensin–aldosterone system causing 
resistant hypertension, endothelial dysfunction, 
inflammation, metabolic factors and genetic 
predisposition [17-23].  
 Possible influence of OSA to the progression 
of resistant hypertension have been looked into by 
several studies. In OSA patients, refractory 
hypertension is primarily systolic and relatively more 
prominent at night [7-9].  Nocturnal raises in systolic 
BP due to OSA may have particular adverse influences 
in patients with refractory hypertension, since night-
time systolic BP forecasts cardiovascular morbidity 
and mortality more precisely than daytime systolic BP.  
 In patients with resistant hypertension, OSA 
evaluation should emphasize on recognizing causative 
factors and excluding other causes of secondary 
(resistant) hypertension [24-27]. In patients with 
significant signs of catecholamine excess in whom a 
catecholamine-producing tumour cannot be 
recognized, a diagnosis of OSA should be considered. 
A tailored and personalized diagnostic evaluation for 
other identifiable causes for each individual should be 
steered by their respective signs and symptoms [30]. 
 A seemingly resistant hypertension, usually 
due to a "white coat hypertension" or "isolated office 
hypertension’’ state (blood pressure raised in the office 
environment but normalized out of the office) must be 
differentiated from exact resistant hypertension. 
Serious overestimation of blood pressure might be 
caused by inability to use proper and correct cuffs on 
OSA patients with large arms [32]. 
 
OSA in diabetic patients 
Among OSA patients, type 2 diabetes mellitus 
(T2DM) have been postulated to be one of the main 
driver that increased risk of cardiovascular morbidity.  
A cross-sectional correlation between OSA severity 
and T2DM prevalence have been identified from 
community and sleep laboratory-based populations 
data [12,13]. A recent cross-sectional study assessing 
the correlations between OSA severity and T2DM 
prevalence in a vast multinational population involving 
6,616 patients in the European Sleep Apnoea Cohort 
(ESADA) analysis have shown that T2DM prevalence 
increased with OSA severity [11, 33].    
 This study also found out that Diabetic 
patients with severe OSA had poorer glycaemic 
control, with adjusted mean HbA1c levels 0.72% 
higher compared to those without sleep-disordered 
breathing (P <0 .001). They also concluded that 
worsening OSA severity is directly correlated with 
increased likelihood of having concomitant T2DM and 
worse diabetic control in subjects with T2DM [11].      
 Another study done amongst 544 participants 
without any pre-existing diabetes assessed in a Yale 
sleep clinic by Botros et al suggested a possible 
contributory role for OSA in propagating the 
development of T2DM.  This population-level data 
showed that a OSA diagnosis conversed a significantly 
increased risk of emerging T2DM over a mean follow-
up period of 2.7 years, despite modification for 
confounding demographic and clinical factors (HR 
1.43 per quartile of OSA severity) [14]. 
OSA amongst obese patients 
The prevalence of OSA is noted to be rising among 
obese patients, given that obesity is the most common 
risk factor in OSA. OSA is closely linked with the 
metabolic syndrome, and it is proposed that OSA 
propagate cardiometabolic dysfunction, and ultimately 
vasculopathy as suggested by recent data. Well-known 
pathophysiological triggers in OSA include alternating 
hypoxia and sleep disturbances. Few possible ways of 
OSA–obesity–metabolic syndrome correlations have 
been proposed, which include activation of 
sympathetic nervous system, presence of oxidative 
stress, inflammatory changes and neurohumoral 
activation involving adiponectin and leptin [32, 33].  
 The data from human and animal/cell studies 
of intermittent hypoxia to describe these pathways are 
accumulating [28-31]. A balanced and healthy food 
intake accompanied by proper lifestyle adjustments 
play important roles in managing metabolic syndrome 
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and are equally important as CPAP usage in OSA 
management as a whole [10, 30]. 
OSA in Asian patients 
Despite being reported as a common disease in 
Western population, surprisingly, the data on OSA 
prevalence in Asian population are still lacking. A 
systematic review on OSA prevalence in Asian 
population by Mirrakhimov et al [6] which included 24 
articles, covering 47, 957 patients have shown that 
OSA prevalence were observed to range from 3.7% to 
97.3%. Several risk factors have been associated with 
OSA among Asian patients, which include male sex, 
elderly patient, high BMI and waist to hip ratio, larger 
neck circumference, presence of arterial hypertension, 
smoking habits, snoring events and daytime 
drowsiness. Differences in prevalence rates among 
previous Asian studies can be explained by different 
sample size, different study populations and different 
inclusion criteria (some studies included subjects with 
a high pre-test probability of OSA). The prevalence of 
snoring, witnessed apnoea, EDS and insomnia, rather 
than OSA diagnosis have been reported by few other 
studies. Thailand has been reported to have the lowest 
snoring prevalence of 4.6% [18] while Taiwan has 
been reported to have the highest prevalence of 59.1% 
[17].  A much higher number of women have been 
included in the study from Thailand[18] and the 
younger subjects were included in the study from 
Taiwan and China [17]. Taiwan was reported to have 
the lowest 2.6% [17], and Malaysia  was reported to 
have the highest prevalence of witnessed apenas of 
15.2%[19]., In Turkish studies, EDS symptoms ranged 
from 3.85% [16] to 24% [15]. Different sample sizes 
and populations studied explained the difference in 
EDS prevalence findings  
 The results of many published studies on 
Asian population evaluated subjects with high pre-test 
probability of OSA; hence their findings may 
overemphasize the exact load of the disease. More 
researches with larger samples are required in order to 
expand our understanding on OSA amongst Asian 
population. 
CONCLUSION 
Obstructive sleep apnoea (OSA) is a progressively 
evolving health threat in both developed and 
developing nations. Major recommendations have 
been suggested for OSA diagnosis and treatment. 
Early identification and management of OSA is 
paramount in reducing cardio metabolic risks in global 
population. Some aspects of pathophysiology and 
correlations of OSA remain unexplored. Future 
research with larger study population are needed to 
establish the OSA correlations and its long-term effect 
especially in specific population.  
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